Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beclovid-C is a topical combination cream manufactured by the Malaysian pharmaceutical company Hovid. It is formulated with three active ingredients: clotrimazole (1%), beclomethasone dipropionate (0.025%), and neomycin. This combination is indicated for the treatment of various inflammatory skin disorders complicated by bacterial and/or fungal infections. Beclomethasone dipropionate is a corticosteroid that reduces inflammation, redness, and itching by activating glucocorticoid receptors. Clotrimazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, thereby disrupting fungal cell membrane integrity. Neomycin is an aminoglycoside antibiotic that prevents bacterial growth by binding to the 30S ribosomal subunit and inhibiting protein synthesis. The product is marketed for topical application to affected skin areas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beclovid-C.